Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525 
 
Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525 
  
 
Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530 
 
Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531 
   English Wikipedia
  Nephropedia Template TP (
  Twit Text
 
  DeepDyve Pubget Overpricing |    
 
  lüll The molecular and cellular biology of thrombopoietin: the primary regulator of  platelet production Kaushansky K; Drachman JGOncogene  2002[May]; 21 (21): 3359-67The term thrombopoietin (TPO) was first coined in 1958 and used to describe the  humoral substance responsible for causing the platelet count to rise in response  to thrombocytopenic stimuli. Despite much progress during the 1980s in the  purification and characterization of the humoral regulators of lymphocyte,  erythrocyte, monocyte and granulocyte production, the successful search to purify  and molecularly clone thrombopoietin did not begin until the oncogene v-mpl was  discovered in 1990. Since that time the proto-oncogene c-mpl was identified and,  based on homology arguments, believed to encode a hematopoietic cytokine  receptor, a hypothesis later proven when the cytoplasmic domain was linked to the  ligand binding domain of the IL-4 receptor and shown to support the IL-4 induced  growth of hematopoietic cells (Skoda et al., 1993). Finally, two different  strategies using c-mpl lead to the identification of a novel ligand for the  receptor in 1994 (de Sauvage et al., 1994; Lok et al., 1994; Bartley et al.,  1994), a protein that displays all the biologic properties of TPO. This review  attempts to distill what has been learned of the molecular and cellular biology  of TPO and its receptor during the past several years, and links this information  to several new insights into human disease and its treatment.|*Neoplasm Proteins[MESH]|*Receptors, Cytokine[MESH]|Alternative Splicing[MESH]|Animals[MESH]|Blood Platelets/*metabolism[MESH]|Clinical Trials as Topic[MESH]|Humans[MESH]|Protein Structure, Tertiary[MESH]|Proto-Oncogene Mas[MESH]|Proto-Oncogene Proteins/physiology[MESH]|Receptors, Interleukin-4/metabolism[MESH]|Receptors, Thrombopoietin[MESH]|Signal Transduction[MESH]|Thrombopoietin/*genetics/*physiology/therapeutic use[MESH] |